T/R ratio for estimation of sample size in BE study of NTI drugs [Power / Sample Size]

posted by mahmoud-teaima  – 2017-10-24 21:18 (2742 d 12:14 ago) – Posting: # 17916
Views: 9,040

Salam to all,
Pease, advise me about what is the best T/R ratio to be used for estimating sample size for a BE study of NTI drugs? knowing that the GL to be followed set the 90% CI acceptance range to (90-111.11) for Cmax if a "2x2x2" design be followed.
I'm confused to use T/R ratio of 0.95 or 0.975?!

+++++++++++ Equivalence test - TOST +++++++++++
            Sample size estimation
-----------------------------------------------
Study design:  2x2 crossover
log-transformed data (multiplicative model)

alpha = 0.05, target power = 0.8
BE margins = 0.9 ... 1.1111
True ratio = 0.95,  CV = 0.0945

Sample size (total)
 n     power
40   0.808788

+++++++++++ Equivalence test - TOST +++++++++++
            Sample size estimation
-----------------------------------------------
Study design:  2x2 crossover
log-transformed data (multiplicative model)

alpha = 0.05, target power = 0.8
BE margins = 0.9 ... 1.1111
True ratio = 0.975,  CV = 0.0945

Sample size (total)
 n     power
20   0.820356


Greetings.

Mahmoud Teaima, PhD.

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
100 visitors (0 registered, 100 guests [including 11 identified bots]).
Forum time: 09:33 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery.    Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5